Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB is a clinical-stage biopharmaceutical company, established in Stockholm, Sweden in 2004. Its core business is to discover, develop, and commercialize pharmaceutical treatments for rare diseases, initially concentrating on conditions affecting the kidneys and liver. The company's portfolio features Nefecon, an oral budesonide immunosuppressant designed to treat immunoglobulin A nephropathy, an autoimmune renal disease. A leading candidate, Setanaxib, a NOX inhibitor, is currently in Phase 2b/3 trials for primary biliary cholangitis, and Phase 2 trials for squamous cell carcinoma of the head and neck, idiopathic pulmonary fibrosis, and type 1 diabetic kidney disease. Additionally, Calliditas develops Budenofalk 3 mg oral capsules for the management of autoimmune hepatitis.

Calliditas Therapeutics AB (publ) trades as CALTX.ST on STO. The company is classified in Healthcare / Biotechnology and reports in SEK.

The current profile places the business in Biotechnology. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Calliditas Therapeutics AB (publ) can be compared against peers such as Abliva AB (publ), Amniotics AB (publ), Biotage AB (publ), Cyxone AB (publ), Idogen AB (publ), InDex Pharmaceuticals Holding AB (publ).

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $11.24B, beta of 1.46, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

CALTX.ST currently shows total debt of N/A and beta of 1.46. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.calliditas.se

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.